The Success Rates From IVF are Nowhere Near What People Think
By Ellie Kincaid,
Business Insider [Australia]
| 05. 29. 2015
Untitled Document
“Test tube babies” are not that rare these days.
The Centres for Disease Control and Prevention estimates that 1.5% of babies born in the US are conceived using what’s called Assisted Reproductive Technology (ART), of which the most common procedure is in vitro fertilization (IVF).
IVF is a procedure in which eggs are taken from a woman’s ovaries and fertilised with sperm in a petri dish. Then one or more fertilised embryos are placed in the woman’s uterus, where one will hopefully implant and grow into a baby.
Though thousands of IVF cycles are done every year in the US, it’s tricky to get a sense of an individual woman’s chance of conceiving with the procedure. The graphs below, from the CDC, show exactly how often IVF resulted in a baby for women who went through the costly treatment using their own eggs, not donor eggs. A single IVF cycle costs an average of $US12,400, according to the American Society for Reproductive Medicine (ASRM), and women often need multiple tries to get pregnant.
About 36% of IVF...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
By Ryan Knutson and Jessica Mendoza, The Journal. | 03.27.2026
Genetically engineered babies are banned in the U.S. But that isn’t stopping Silicon Valley tech titans from trying to make one. In this final installment from The Journal’s investigation into the fringes of the fertility industry, WSJ’s Emily Glazer reports...
By Antonio Regalado, MIT Technology Review | 03.30.2026
After operating in secrecy for years, a startup company called R3 Bio, in Richmond, California, suddenly shared details about its work last week—saying it had raised money to create nonsentient monkey “organ sacks” as an alternative to animal testing.
In...
